Clinical trials: Neoplasms, Pharyngeal
Head and Neck Cancer
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00833261
- Testing
- cetuximab, cisplatin, intensity-modulated radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Texas Southwestern Medical Center
Nasopharyngeal Carcinoma
Magnifying NBI for Occult NPC
Diagnosis of nasopharyngeal carcinoma (NPC) is currently made by trans-nasal endoscopy and biopsy. The small caliber endoscope provides only a limited view of the nasopharynx and may not be able to provide a thorough assessment…
- Trial name
- NCT04593186
- Testing
- Trans-oral magnifying endoscopy with NBI
- Where
- Hong Kong
- Volunteers
- 246 people
- Sponsor
- Chinese University of Hong Kong
Oropharyngeal Neoplasms
Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity
This study looks at the use of three cycles of chemotherapy given prior to radiation therapy in patients with cancer of the oral cavity and evidence of prior exposure to Human Papilloma Virus (HPV).
- Trial name
- NCT01525927
- Testing
- chemotherapy, radiotherapy, Reduced dose radiotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwell Health
Laryngeal Neoplasms, Hypopharyngeal Neoplasms
Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA
Organ Preservation: Weekly Carboplatin \& Taxol w/concurrent RT for locally advanced laryngeal \& Hypopharyngeal CA
- Trial name
- NCT00534729
- Testing
- Weekly Carboplatin & Taxol w/concurrent RT
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Nasopharyngeal Carcinoma
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
The purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO) strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC).
- Trial name
- NCT03097939
- Testing
- Ipilimumab, Nivolumab
- Where
- Singapore
- Volunteers
- 113 people
- Sponsor
- National Cancer Centre, Singapore
Cancer-related Problem/Condition, Head and Neck Cancer
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
RATIONALE: Glutamine may be effective in decreasing side effects, such as inflammation of the mouth and throat, caused by radiation therapy. The effectiveness of glutamine for mucositis is not yet known.
- Conditions
- Cancer-related Problem/Condition, Head and Neck Cancer, Pain
- Trial name
- NCT00006994
- Testing
- glutamine, radiation therapy
- Where
- 107 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- SWOG Cancer Research Network
Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
Reactivating NK Cells in Treating Refractory Head and Neck Cancer
This study aims to determine the safety and efficacy of expanded activated autologous NK cells administered after cetuximab in patients with EGFR-positive nasopharyngeal carcinoma or head and neck squamous cell carcinoma.
- Trial name
- NKEXPHNC (NCT02507154)
- Testing
- Cetuximab + NK cells
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Neoplasms
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients
A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer. However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma…
- Trial name
- NCT02505139
- Testing
- the number of circulating tumor cells
- Volunteers
- 166 people
- Sponsor
- Sun Yat-sen University
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Oropharynx Cancer, Frailty
Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly
Previous studies of this type of head and necl cancer have shown high rates of cancer control but result in many short and long term side effects when treated with high dose radiation and chemotherapy.
- Trial name
- (DACHOC-E) (NCT06309225)
- Testing
- Modified dose and fields intensity modulated radiotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Omar Mahmoud
Oropharyngeal Cancer
PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC
More and more studies have shown that the efficacy and prognosis of HPV （Human papillomavirus）-positive oropharyngeal cancer (OPC) patients are better than those of others.
- Trial name
- NCT06156891
- Testing
- Toxicities reduced treatment, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Colorectal Cancer, Triple Negative Breast Cancer
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma, Nasopharyngeal Carcinoma
- Trial name
- NCT04107142
- Testing
- Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Head and Neck Cancer, Tobacco Use Disorder
Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use
RATIONALE: A counseling program that motivates patients to stop smoking and drinking may reduce the risk of oral cancer. It is not yet known whether motivational stop smoking counseling or motivational stop-smoking and stop…
- Trial name
- NCT00799669
- Testing
- smoking cessation intervention, counseling intervention, preventive intervention
- Volunteers
- 370 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Radiation Toxicity
Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer
RATIONALE: Electroacupuncture may help relieve chronic dry mouth caused by radiation therapy. It is not yet known whether electroacupuncture is more effective than a placebo in treating chronic dry mouth caused by radiation…
- Conditions
- Head and Neck Cancer, Radiation Toxicity, Xerostomia
- Trial name
- NCT00623129
- Testing
- questionnaire administration, electroacupuncture therapy, management of therapy complications
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Nasopharyngeal Cancinoma (NPC)
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.
- Trial name
- NCT07067268
- Testing
- Adjuvant therapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma, Herpesvirus 4, Human
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
The investigators aim to explore a new EBV DNA surveillance method with both high sensitivity and specificity in nasopharyngeal carcinoma (NPC) patients.
- Trial name
- NCT06321939
- Testing
- EBV-DNA next generation sequencing
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hunan Cancer Hospital
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
The purpose of this study is to test the safety and tolerability of chemotherapy and radiation in combination with the investigational study drugs zimberelimab (AB122) and etrumadenant (AB928) in subjects with a locally advances…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oral Cavity Cancer
- Trial name
- PANTHEoN (NCT04892875)
- Testing
- Zimberelimab, Etrumadenant, Cisplatin
- Sponsor
- Jennifer Choe
Colorectal Cancer, Nasopharyngeal Cancer
A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer
1. To determine the association between LVD and clinico-pathologic variables in archived colorectal cancer and Nasopharyngeal carcinoma specimens 2.
- Trial name
- NCT00943891
- Testing
- Tumor biopsies
- Where
- Singapore
- Volunteers
- 500 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma, NPC
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated.
- Conditions
- Nasopharyngeal Carcinoma, NPC, EBV, Radiotherapy
- Trial name
- NCT03973723
- Where
- Taiwan
- Volunteers
- 441 people
- Sponsor
- Taichung Veterans General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.